Your session is about to expire
← Back to Search
Cabozantinib + Nivolumab for Lung Cancer
Study Summary
This trial is testing cabozantinib with or without nivolumab versus standard chemotherapy in patients with non-squamous non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 2 trial • 13 Patients • NCT02315430Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What kind of diseases is Cabozantinib S-malate frequently employed in the management of?
"Cabozantinib S-malate is primarily administered to treat mediastinitis and has also been found to have efficacy in counteracting small cell lung cancer, unresponsive melanoma, and squamous cell carcinoma."
Are any additional participants being welcomed into this medical trial?
"As per the information listed on clinicaltrials.gov, this research is currently recruiting patients and was originally published on May 22nd 2020 before being modified for the last time on November 25th 2022."
To what extent has Cabozantinib S-malate been explored by researchers?
"In 1997, the City of Hope Comprehensive Cancer Center began exploring cabozantinib S-malate. To date, there has been a total of 2,947 completed studies; today 2102 are still active with many taking place in Racine Wisconsin."
What is the uppermost capacity of participants for this clinical trial?
"Affirmative. According to clinicaltrials.gov, this health research is presently recruiting participants after first being published on the 22nd of May 2020 and lastly updated on 25th November 2022. 142 volunteers are needed from a hundred spots around the country."
Has Cabozantinib S-malate obtained governmental endorsement?
"As a Phase 2 trial, there is some evidence that cabozantinib s-malate is safe to use; this safety was assigned a score of two. However, no data has been collected yet to support the efficacy of this drug."
To what extent is this research study being conducted across the country?
"Currently, this medical trial is accepting enrolment from 100 separate sites. Of these centres, three are located in Racine, Carthage and Burlington but the other 97 can be found throughout a variety of locations. Therefore it might prove beneficial to select the closest site for you to minimise travel burdens if you choose to participate in research."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Stanford Cancer Institute Palo Alto: < 24 hours
Average response time
- < 1 Day
Share this study with friends
Copy Link
Messenger